Ivermectin Role in Covid-19 Clinical Trial

Elaraby Hospital300 enrolled

Overview

Because ivermectin is being used to treat COVID-19 with insufficient evidence, the investigator conducted a randomized clinical trial to investigate the efficacy and safety of ivermectin in comparison to hydroxychloroquine and placebo in severe COVID-19 patients. The study was conducted in Shebin-Elkom teaching hospital and recruited patients from December 6, 2020, to January 31, 2021.

This study is an adaptive, randomized, double-blinded, controlled trial to evaluate the safety and efficacy of therapeutic agents in hospitalized adult patients diagnosed with COVID-19. The study is a single-center trial that will be conducted in Shebin Elkom teaching hospital. The study will be a series of 3-arm comparisons between two different investigational therapeutic agents (Ivermectin and Hydroxychloroquine) and a placebo. There will be interim monitoring to allow early stopping for futility, efficacy, or safety. Because of the possibility that background standards of supportive care may evolve/improve over time as more is learned about the successful management of COVID-19, comparisons of safety and efficacy will be based on data from concurrently randomized participants. An independent data and safety monitoring board (DSMB) will actively monitor interim data to make recommendations about early study closure or changes to study arms.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

300

Conditions

Covid19

Interventions

ivermectinDRUG

ivermectin is anthelmintic

hydroxychloroquineDRUG

hydroxychloroquine is antimalarial.

PlaceboDRUG

Standard treatments

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. 2. Understands and agrees to comply with planned study procedures. 3. Agrees to the collection of OP swabs and venous blood per protocol. 4. Male or non-pregnant female adult ≥18 years of age at time of enrollment. 5. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other 6. Severe cases according to WHO definition. Exclusion Criteria: 1. ALT/AST \> 5 times the upper limit of normal. 2. Mortality within 12 hours of admission. 3. Pregnancy. 4. Anticipated transfer to another hospital within 24 hours. 5. Allergy to any study medication commercial or public health assay in any specimen prior to randomization. 6. Mechanically ventilated on admission

Locations (1)

Shebin-Elkom teaching hospital

Shibīn al Kawm, Menoufia, Egypt

Outcomes

Primary Outcomes

Reduction in the WHO ordinal scale of clinical status by at least two points

The ordinal scale consists of 7 points, the maximum score is 7 which indicates a worst outcome, while the minimum score is 1 which indicates a better outcome

Time frame: 14 days

Time to discharge

time to discharge to home after no more need for hospitalization

Time frame: within 14 days

Secondary Outcomes

Mortality

All-causes mortality

Time frame: 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.